Company & Sponsor Intelligence
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed1
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT00021723Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT00937352A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →